[Heparin-associated thrombocytopenia caused by low-molecular-weight heparin].
Recent studies have shown that low-molecular-weight heparins (LMWH) are not suitable for treating patients with heparin-associated thrombopenia (HAT) type 2, as they can cause the same complications as unfractionated heparin UFH. The case described ist that of concerns as female patient who died after developing HAT type 2 following LMWH given perioperatively to prevent thromboembolism. This case indicates again that LMWH can trigger HAT type 2 even if administered only once a day. For HAT to be successfully treated it is essential that the condition is diagnosed early enough by means of routine regular laboratory checks of the number of thrombocytes during any heparin treatment in order to detect the disease before clinical symptoms become apparent.
Köninger
J
J
Chirurgische Klinik, Bürgerhospital Stuttgart.
Greinacher
A
A
Müller-Beissenhirtz
W
W
Strosche
H
H
D000368:Aged; D017809:Fatal Outcome; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects*; D006622:Hip Prosthesis; D006801:Humans; D015207:Osteoarthritis, Hip / Q000097:blood / Q000601:surgery; D010976:Platelet Count / Q000187:drug effects; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control*; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*; D013924:Thrombophlebitis / Q000097:blood / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight
Heparin-assoziierte Thrombozytopenie durch niedermolekulare Heparine.